FRI0584 Rheumatic and musculoskeletal disorders related to immune checkpoint inhibitors in cancer patients: a prospective single-institution study
Khaled marie(Hôpital Pellegrin), Thierry Schaeverbeke(Centre Hospitalier Universitaire de Bordeaux), Marine Gross‐Goupil(Université de Bordeaux), Florent Martin(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Christophe Richez(Centre National de la Recherche Scientifique), B Bannwarth(Centre Hospitalier Universitaire de Bordeaux), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Nadia Mehsen-Cêtre(Bordeaux Population Health), M. Beylot‐Barry(Université de Bordeaux), L. Rouxel(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Université de Bordeaux)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k